A Study of MEN2501 for Platinum-Resistant Ovarian Cancer
This study is testing a new oral tablet called MEN2501 in people with platinum-resistant ovarian cancer. This means your cancer has not responded well to platinum-based chemotherapy. The study aims to find a safe and effective dose of MEN2501. Researchers will look at how safe MEN2501 is and how well your body handles it. They will also see if it can shrink tumors. You may be able to join if you are an adult woman with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer that is platinum-resistant. The study is currently not clear on its recruitment status.
- Study design
- This is a first-in-human, open-label (meaning you and your doctors will know what treatment you are receiving) study. It will involve about 100 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure the recommended dose for up to approximately 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
At a glance
Conditions
Where it's being run
15 sites across 10 statesStudy leadership
- Medical Director · STUDY_DIRECTOR · Stemline Therapeutics, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Part A Only: Number of Participants with Dose-limiting Toxicities (DLTs)Cycle 1 (28 days/cycle)
- Part B Only: Recommended Phase 2 Dose (RP2D) of MEN2501Up to approximately 6 months